IV INTERNATIONAL CONFERENCE ON AIDS
JUNE 12-16, 1988, STOCKHOLM, SWEDEN

TITLE ............... Phosphorothioate Analogs of Oligodeoxynucleotide Inhibit Viral Replication of Human Immunodeficiency Virus (HIV): Inhibition of de novo Infection in Uninfected Cells and Regulation of Viral Expression in Chronically Infected Cells

AUTHORS .............. Makoto Matsukura, Kazuo Shinozuka, Gerald Zon**, Hiroaki Mitsuya, Flossie Wong-Staal*, Cy Stein, Jack S. Cohen, and Samuel Broder

ADDRESSES ............. Clinical Oncology Program
and
*Laboratory of Tumor Cell Biology,
National Cancer Institute,
National Institutes of Health, Bethesda, Md., USA

**Applied Biosystems, Inc., Foster City, Calif., USA
and

TITLE ............... Physiochemical Properties of Phosphorothioate Oligodeoxynucleotide Anti-HIV Agents

AUTHORS .............. Cy Stein, Chrisanthi Subasinghe, Kazuo Shinozuka, and Jack S. Cohen

ADDRESSES ............. Clinical Oncology Program,
National Cancer Institute,
National Institutes of Health, Bethesda, Md., USA

FOR MORE INFORMATION
(301) 496-6641
FOR RELEASE AT TIME
OF PRESENTATION

STOCKHOLM—Modified analogs of oligodeoxynucleotides (ODNs) inhibit the AIDS virus from reproducing in infected T cells as well as from infecting normal T cells, scientists from the U.S. National Cancer Institute (NCI) reported today.

(more)
The analogs are novel because most other potential antiviral agents under study are aimed at inhibiting the AIDS virus from infecting normal cells, but they do not have an effect on already infected cells.

"The analogs are capable of inhibiting both viral infection in uninfected T cells and viral expression in chronically infected cells," said Makoto Matsukura, M.D., reporting on the study at the 4th International Conference on AIDS in Stockholm. The study was conducted by Dr. Matsukura, Dr. Samuel Broder, and colleagues at NCI, Bethesda, Md., in collaboration with Applied Biosystems Inc., Foster City, Calif.

Much further laboratory research will be needed to develop an appropriate treatment regimen for patients with AIDS or AIDS-related complex.

"The analogs, called phosphorothioate ODNs (S-ODNs), are short modified DNA sequences that are complementary, or 'antisense,' to a gene of the AIDS virus that is essential for the virus to replicate," Dr. Matsukura said. "The analogs bind to the viral gene art/trs, stopping the gene's activity and, thus, the virus's ability to replicate."

In a 1987 study, Dr. Matsukura and colleagues unexpectedly found that S-ODNs that did not match the RNA of art/trs gene still inhibited the virus from infecting normal T cells.* This finding, along with the findings reported today, suggests that the analogs have at least two ways of inhibiting the AIDS virus--an antisense way and some other way," Dr. Matsukura said. The precise mechanisms by which this happens are not fully understood.

Reporting on related research at the AIDS conference, NCI's Dr. Jack Cohen described the results of a detailed study on the physical and chemical


(more)
properties of S-ODNs. The analogs are very hardy. They do not appear to be easily degraded (destroyed) by enzymes like unmodified ODNs. At body temperature, they form stable bonds with the AIDS viral gene. Characteristics such as these may be important assets for an effective AIDS therapy, Dr. Matsukura said, but much work still needs to be done before such compounds can be used in patients.

The idea of using ODN as an antisense agent to inhibit viral replication was introduced in the late 1970s by Dr. Paul Zamecnik at the Worcester Foundation for Experimental Biology, Shrewsbury, Mass., and colleagues. After the AIDS virus was discovered, NCI scientists began developing and studying modified DNA versions of ODN that were specific for the AIDS virus.